Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines

Oral Oncology

Volumn 49, Issue 9, 2013, Pages 872-877

  D'Cruz, A ^a   Lin, T ^b   Anand, A K ^c   Atmakusuma, D ^d   Calaguas, M J ^e   Chitapanarux, I ^f   Cho, B C ^g   Goh, B C ^h   Guo, Y ⁱ   Hsieh, W S ^j   Hu, C ⁱ   Kwong, D ^k   Lin, J C ^l   Lou, P J ^m   Lu, T ^b   Prabhash, K ^a   Sriuranpong, V ⁿ   Tang, P ^o   Vu, V V ^p   Wahid, I ^q   Ang, K K ^r   Chan, A T ^s   more..

^a TATA MEMORIAL HOSPITAL   (India)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c Max Hospital   (India)

^d CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^e ST LUKE S MEDICAL CENTER   (Philippines)

^f Maharaj Nakorn Chiangmai Hospital   (Thailand)

^g Yonsei University College of Medicine   (South Korea)

^h NATIONAL UNIVERSITY HOSPITAL   (Singapore)

ⁱ FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^j Singapore Oncology Consultants   (Singapore)

^k UNIVERSITY OF HONG KONG   (Hong Kong)

^l TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^m NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁿ CHULALONGKORN UNIVERSITY   (Thailand)

^o PEKING UNION MEDICAL COLLEGE   (China)

^p Ho Chi Minh City Oncology Hospital   (Viet Nam)

^q Beacon International Specialist Centre   (Malaysia)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^s CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

Asia; Guidelines; Head and neck cancer

Indexed keywords

BLEOMYCIN; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ASIA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; ENDOSCOPIC SURGERY; HEAD AND NECK CANCER; HEALTH CARE PERSONNEL; HUMAN; HYPOPHARYNX CARCINOMA; INTENSITY MODULATED RADIATION THERAPY; LARYNGECTOMY; LARYNX CANCER; LIP CANCER; MEDICAL SOCIETY; METASTASIS; MOUTH CANCER; MOUTH CAVITY; NASOPHARYNX CANCER; NECK DISSECTION; OROPHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THYROIDECTOMY;

ASIA; GUIDELINES; HEAD AND NECK CANCER;

ASIA; CONSENSUS; HEAD AND NECK NEOPLASMS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 84883133202     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.05.010     Document Type: Review

References (31)

1. V. Gregoire, J.-L. Lefebvre, L. Licitra, and E. Felip On behalf of the EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v184 v186
2. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. < http://globocan.iarc.fr > [accessed 21.01.13].
4. A. Alvi, E.N. Myers, and J.T. Johnson Cancer of the Oral Cavity E.N. Myers, J.Y. Suen, Cancer of the head and neck 1996 W.B. Saunders Company Philadelphia 321 361
5. S.T. Mayne, D.E. Morse, and D.M. Winn Cancers of the oral cavity and pharynx D. Schottenfeld, F.J. Fraumeni, Cancer epidemiology and prevention 3rd ed. 2006 Oxford Univ Press
6. A.R. Kreimer, G.M. Clifford, P. Boyle, and S. Franceschi Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review Can Epidemiol Biomarkers Prev 14 2 2005 467 475
7. Head and Neck Cancers. < http://www.cancer.gov/cancertopics/factsheet/ Sites-Types/head-and-neck > [accessed 21.01.13].
8. X.N. Zou, S.H. Lu, and B. Liu Volatile N-nitrosamines and their precursors in Chinese salted fish - a possible etological factor for NPC in China Int J Cancer 59 2 1994 155 158
9. M.J. Worsham Identifying the risk factors for late-stage head and neck cancer Expert Rev Anticancer Ther 11 9 2011 1321 1325
10. J.P. Pignon, A. Le Maitre, E. Maillard, and J. Bourhis Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol 92 2009 4 14
11. B. Brockstein, D.J. Haral, A.W. Rademaker, M.S. Kies, K.M. Stenson, and F. Rosen Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience Ann Oncol 15 2004 1179 1186
12. Ridge JA, Glisson BS, Lango MN, Feigenberg S. Head and neck tumors. Cancer management, 14th ed.; 2011. < www.cancernetwork.com/display/article/ 10165/1802498 >.
13. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Head and Neck Cancers. Version 2.2011. < http://www. oralcancerfoundation.org/treatment/pdf/head-and-neck.pdf > [accessed 21.01.13].
14. Z. Gil, and D.M. Fliss Contemporary management of head and neck cancers Isr Med Assoc J 11 2009 296 300
15. A.T.C. Chan, V. Gregoire, J.-L. Lefebvre, L. Licitra, and E. Felip On behalf of the EHNS-ESMO-ESTRO guidelines working group. Nasopharyngeal cancer: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v187 189
16. J. Lefebvre, Y. Pointreau, F. Rolland, M. Alfonsi, A. Baudoux, and C. Sire Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study J Clin Oncol 29 Suppl. 2011 [Abstr 5501]
17. J.B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, and S. Rottey Platinum-based chemotherapy plus cetuximab in head and neck cancer New Engl J Med 359 2008 1116 1127
18. Y. Gao, G. Zhu, J. Lu, H. Ying, L. Kong, and Y. Wu Is elective irradiation to the lower neck necessary for N0 nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys 77 2010 1397 1402
19. S.H. Cheng, K.L. Yen, J.J. Jian, Sy Tsai, N.M. Chu, and S.Y. Leu Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials Int J Radiat Oncol Biol Phys 50 2001 717 726
20. S.H. Cheng, S.Y. Tsai, C.F. Horng, K.L. Yen, J.J. Jian, and K.Y. Chan A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy Int J Radiat Oncol Biol Phys 66 2006 992 1003
21. J.C. Lin, W.M. Liang, J.S. Jan, R.S. Jiang, and A.C. Lin Another way to estimate outcome of advanced nasopharyngeal carcinoma - is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 60 2004 156 164
22. D.L.W. Kwong, J.S.T. Sham, G.K.H. Au, D.T.T. Chua, P.W.K. Kwong, and A.C.K. Cheng Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study J Clin Oncol 22 2004 2643 2653
23. F. Perri, D. Bosso, C. Buonerba, G. Di Lorenzo, and G.D.V. Scarpati Locally advanced nasopharyngeal carcinoma: current and emerging treatment strategies World J Clin Oncol 2 12 2011 377 383
24. L. Chen, C.S. Hu, X.Z. Chen, G.Q. Hu, Z.B. Cheng, and Y. Sun Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial Lancet Oncol 13 2012 163 171
25. B.B.Y. Ma, M.K.M. Kam, S.F. Leung, E.P. Hui, A.D. King, and S.L. Chan A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma Ann Oncol 23 2012 1287 1292
26. C.Y. Chen, C. Zhao, L. Gao, J.Y. Lang, J.J. Pan, and C.S. Hu An open-labelled, multicentric clinical study of cetuximab combined with intensity-modulated radiotherapy (IMRT) plus concurrent chemotherapy in locoregionally advanced (LA) nasopharyngeal carcinoma (NPC): a 2-year follow-up report J Clin Oncol 30 2012 Suppl; Abstr 5535
27. A.T. Chan, M.M. Hsu, B.C. Goh, E.P. Hui, T.W. Liu, and M.J. Millward Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma J Clin Oncol 23 15 2005 3568 3576
28. S.F. Leung, B. Zee, B.B. Ma, E.P. Hui, M. Lai, and K.C. Chan Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma J Clin Oncol 24 2006 5414 5418
29. J.C. Lin, W.Y. Wang, K.Y. Chen, Y.H. Wei, W.M. Laing, and J.S. Jan Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma New Engl J Med 350 2004 2461 2470
30. J.C. Lin, W.Y. Wang, W.M. Liang, H.Y. Chou, J.S. Jan, and R.S. Jiang Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy Int J Radiat Oncol Biol Phys 68 2007 1342 1348
31. A.T. Chan, Y.M. Lo, B. Zee, L.Y. Chan, B.B. Ma, and S.F. Leung Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma J Natl Cancer Inst 94 21 2002 1614 1619